亚太药业(002370.SZ)：二级子公司变为一级子公司并注销

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) has signed a share transfer agreement with its wholly-owned subsidiary Wuhan Guanggu Asia-Pacific Pharmaceutical Co., Ltd., transferring 100% equity of Shaoxing Yatai Pharmaceutical Technology Co., Ltd. for a nominal price of 1 yuan, as Yatai Pharmaceutical currently has negative net assets [1] Group 1 - The share transfer will change Yatai Pharmaceutical from a secondary wholly-owned subsidiary to a primary wholly-owned subsidiary of Asia-Pacific Pharmaceutical [1] - The company plans to optimize its organizational structure and improve operational management efficiency by liquidating Shaoxing Yatai Pharmaceutical Technology Co., Ltd. [1] - Management or authorized personnel will be granted the authority to handle the relevant matters for the subsidiary's liquidation [1]